Compare NAVI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAVI | PHAR |
|---|---|---|
| Founded | 1973 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.4M | 793.4M |
| IPO Year | 2014 | 2020 |
| Metric | NAVI | PHAR |
|---|---|---|
| Price | $9.13 | $10.41 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $10.00 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 1.2M | 27.6K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $271,000,000.00 | N/A |
| Revenue This Year | $76.23 | $10.04 |
| Revenue Next Year | $15.73 | $2.51 |
| P/E Ratio | ★ $21.14 | $3,041.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.33 | $9.62 |
| 52 Week High | $13.50 | $21.34 |
| Indicator | NAVI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 40.15 |
| Support Level | $7.91 | $9.62 |
| Resistance Level | $9.74 | $13.51 |
| Average True Range (ATR) | 0.34 | 0.48 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 19.09 | 10.39 |
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.